Table 1.
Correlation of AKIP1 expression with characteristics of AML patients
| Characteristics | AML patients | AKIP1 expressiona | P value | |
|---|---|---|---|---|
| High | Low | |||
| No. of patients | 291 | 146 | 145 | |
| Age (y), No. (%) | ||||
| <45 | 153 (52.6) | 71 (46.4) | 82 (53.6) | .176 |
| ≥45 | 138 (47.4) | 75 (54.3) | 63 (45.7) | |
| Gender, No. (%) | ||||
| Male | 156 (53.6) | 79 (50.6) | 77 (49.4) | .863 |
| Female | 135 (46.4) | 67 (49.6) | 68 (50.4) | |
| FAB classification, No. (%) | ||||
| M1 | 1 (0.3) | 0 (0.0) | 1 (100.0) | .410 |
| M2 | 108 (37.1) | 50 (46.3) | 58 (53.7) | |
| M4 | 73 (25.1) | 38 (52.1) | 35 (47.9) | |
| M5 | 93 (32.0) | 47 (50.5) | 46 (49.5) | |
| M6 | 16 (5.5) | 11 (68.8) | 5 (31.3) | |
| Normal karyotype, No. (%) | ||||
| No | 142 (48.8) | 71 (50.0) | 71 (50.0) | .954 |
| Yes | 149 (51.2) | 75 (50.3) | 74 (49.7) | |
| inv(16) or t(16;16), No. (%) | ||||
| No | 268 (92.1) | 135 (50.4) | 133 (49.6) | .815 |
| Yes | 23 (7.9) | 11 (47.8) | 12 (52.2) | |
| t(8;21), No. (%) | ||||
| No | 273 (93.8) | 141 (51.6) | 132 (48.4) | .050 |
| Yes | 18 (6.2) | 5 (27.8) | 13 (72.2) | |
| t(9;11), No. (%) | ||||
| No | 283 (97.3) | 142 (50.2) | 141 (49.8) | .992 |
| Yes | 8 (2.7) | 4 (50.0) | 4 (50.0) | |
| t(9;22), No. (%) | ||||
| No | 287 (98.6) | 145 (50.5) | 142 (49.5) | .311 |
| Yes | 4 (1.4) | 1 (25.0) | 3 (75.0) | |
| Complex karyotype, No. (%) | ||||
| No | 263 (90.4) | 131 (49.8) | 132 (50.2) | .705 |
| Yes | 28 (9.6) | 15 (53.6) | 13 (46.4) | |
| +8, No. (%) | ||||
| No | 278 (95.5) | 139 (50.0) | 139 (50.0) | .786 |
| Yes | 13 (4.5) | 7 (53.8) | 6 (46.2) | |
| −7 or 7q−, No. (%) | ||||
| No | 279 (95.9) | 135 (48.4) | 144 (51.6) | .003 |
| Yes | 12 (4.1) | 11 (91.7) | 1 (8.3) | |
| 11q23, No. (%) | ||||
| No | 284 (97.6) | 141 (49.6) | 143 (50.4) | .255 |
| Yes | 7 (2.4) | 5 (71.4) | 2 (28.6) | |
| −5 or 5q−, No. (%) | ||||
| No | 288 (99.0) | 143 (49.7) | 145 (50.3) | .083 |
| Yes | 3 (1.0) | 3 (100.0) | 0 (0.0) | |
| Others (not included in better or poor risk), No. (%) | ||||
| No | 262 (90.0) | 134 (51.1) | 128 (48.9) | .318 |
| Yes | 29 (10.0) | 12 (41.4) | 17 (58.6) | |
| Monosomal karyotype, No. (%) | ||||
| No | 271 (93.1) | 131 (48.3) | 140 (51.7) | .021 |
| Yes | 20 (6.9) | 15 (75.0) | 5 (25.0) | |
| FLT3‐ITD mutation, No. (%) | ||||
| No | 228 (78.4) | 112 (49.1) | 116 (50.9) | .496 |
| Yes | 63 (21.6) | 34 (54.0) | 29 (46.0) | |
| Biallelic CEBPA mutation, No. (%) | ||||
| No | 260 (89.3) | 132 (50.8) | 128 (49.2) | .555 |
| Yes | 31 (10.7) | 14 (45.2) | 17 (54.8) | |
| NPM1 mutation, No. (%) | ||||
| No | 191 (65.6) | 98 (51.3) | 93 (48.7) | .592 |
| Yes | 100 (34.4) | 48 (48.0) | 52 (52.0) | |
| Risk stratification, No. (%) | ||||
| Better‐risk | 80 (27.5) | 29 (36.2) | 51 (63.8) | .002 |
| Intermediate‐risk | 121 (41.6) | 60 (49.6) | 61 (50.4) | |
| Poor‐risk | 90 (30.9) | 57 (63.3) | 33 (36.7) | |
Comparison was determined by chi‐square test or Wilcoxon rank‐sum test.
Abbreviations: AKIP1, A‐kinase interacting protein 1; AML, acute myeloid leukemia; CEBPA, CCAAT/enhancer‐binding protein α; FAB classification, French‐American‐British classification; FLT3‐ITD, internal tandem duplications in the FMS‐like tyrosine kinase 3; NPM1, nucleophosmin; SD, standard deviation.
a
High or low expression of AKIP1 was classified by the median value of AML patients.